Evidence check: CYP2C19 in the context of Darmgesundheit

CYP2C19 is a drug-metabolizing enzyme that breaks down proton pump inhibitors (PPIs) like omeprazole. In the context of gut health, its relevance is indirect: long-term PPI use alters the gut microbiome (increases Enterococcus, reduces diversity) and raises risk for C. difficile infections and nutrient malabsorption (B12, magnesium, iron). Carriers of 'slow metabolizer' variants (e.g., *2/*3) have higher PPI exposure, potentially amplifying microbiome shifts. However, the single-gene effect is small; clinical utility for personalized gut health advice is unproven by RCTs. Evidence is mechanistic (pharmacokinetics) and based on association studies, not on tailored dietary or probiotic recommendations. Caveat: Without PPI use, CYP2C19 has little direct impact on gut health. A DNA test alone is not actionable.